US FDA approves belimumab for the treatment of active lupus nephritis

The approval, which was based on results from the BLISS-LN trial, extends the current indication of belimumab in the US to include both SLE and lupus nephritis for both the IV and subcutaneous formulations (currently approved in the UK for SLE only).

Source:

Biospace Inc.